Cantor Fitzgerald Raises Bristol Myers Squibb (NYSE:BMY) Price Target to $54.00

Bristol Myers Squibb (NYSE:BMY) had its price objective upped by equities research analysts at Cantor Fitzgerald from $45.00 to $54.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target indicates a potential downside of 9.22% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on BMY. Guggenheim restated a “buy” rating and issued a $72.00 price target on shares of Bristol Myers Squibb in a research note on Wednesday. Citigroup raised their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research note on Friday, February 6th. Morgan Stanley reiterated an “underweight” rating and set a $40.00 target price on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Royal Bank Of Canada initiated coverage on shares of Bristol Myers Squibb in a research report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 target price on the stock. Finally, Bank of America upgraded shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $52.00 to $61.00 in a research report on Monday, December 15th. Nine research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Bristol Myers Squibb has an average rating of “Hold” and an average price target of $61.71.

Bristol Myers Squibb Trading Up 0.5%

Shares of Bristol Myers Squibb stock opened at $59.48 on Wednesday. The company has a market capitalization of $121.45 billion, a price-to-earnings ratio of 17.24, a PEG ratio of 0.17 and a beta of 0.27. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. Bristol Myers Squibb has a 12-month low of $42.52 and a 12-month high of $62.89. The firm’s 50-day moving average price is $59.70 and its two-hundred day moving average price is $53.02.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The firm had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company’s quarterly revenue was up 1.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, analysts forecast that Bristol Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the sale, the executive vice president directly owned 159,248 shares in the company, valued at $9,820,824.16. This trade represents a 15.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.09% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in BMY. Swiss RE Ltd. bought a new position in Bristol Myers Squibb during the 4th quarter worth approximately $25,000. Darwin Wealth Management LLC bought a new position in Bristol Myers Squibb during the 2nd quarter worth approximately $25,000. Physician Wealth Advisors Inc. raised its holdings in Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 202 shares during the last quarter. Harbor Capital Advisors Inc. raised its holdings in Bristol Myers Squibb by 107.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 313 shares during the last quarter. Finally, Bayban bought a new position in Bristol Myers Squibb during the 4th quarter worth approximately $31,000. Institutional investors own 76.41% of the company’s stock.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Cobenfy shows commercial traction — 2025 sales of roughly $155M, outpacing peers and supporting upside from label expansion and new indications, which strengthens BMY’s growth outlook. Does Cobenfy Have the Potential to Become a Top Drug for BMY?
• Positive Sentiment: New Oxford BioTherapeutics collaboration to discover next‑gen T‑cell engagers for solid tumors — deal includes upfront, milestones and royalties and validates BMS’s oncology partnering strategy. This could expand pipeline optionality and future revenue streams. Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours
• Positive Sentiment: Guggenheim reaffirmed a “buy” and a $72 price target, supporting optimism among some sell‑side investors about longer-term upside. Guggenheim Reaffirms Buy on BMY
• Neutral Sentiment: Bank of America trimmed its price target slightly (from $68 to $67) but kept a “buy” rating — modest tweak that doesn’t change the positive rating but narrows near‑term upside. BofA Price Target Change
• Neutral Sentiment: BofA note that biopharma names are largely exempt from proposed pharma tariffs — reduces a macro policy risk for large-cap drugmakers like BMY. Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says
• Negative Sentiment: Q1 earnings risk — Street previews point to a potential double‑digit drop in Q1 EPS, a near‑term catalyst that could pressure the stock if results miss expectations. Bristol-Myers Squibb Earnings Preview: What to Expect
• Negative Sentiment: Cantor Fitzgerald raised its target from $45 to $54 but reiterated a Neutral rating and flagged a weak Q1 catalyst — the note highlights limited near‑term upside. Cantor Fitzgerald Lifts Bristol Myers (BMY) Price Target but Flags Weak Q1 Catalyst

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.